Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

The pharmaceutical industry faces significant challenges as Novo Nordisk and Eli Lilly grapple with trial setbacks and market ...

Mindy McCormick, 67, read that her insurer would soon stop covering the weight loss drug Wegovy, which she had been taking for more than two years. Nearly 9,000 people across the state had received ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first ... Zepbound, similar ...

US regulators on Friday approved the first drug treatment for sleep apnea, permitting the use of a weight-loss medication for ...

Eli Lilly & Co.’s weight-loss shot Zepbound won approval in the US as the first drug to treat sleep apnea, opening the door ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Shares of Ozempic-maker Novo Nordisk were down more than 20% in recent trade as the Danish drugmaker headed for its worst day since the 1980s. The stock took a hit after a late-stage trial showed that ...